NCT00589420View on ClinicalTrials.gov

Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 27, 2007

Primary Completion Date

February 2, 2010

Study Completion Date

February 2, 2011

Conditions
Prostate Cancer
Interventions
DRUG

docetaxel

DRUG

sorafenib tosylate

Trial Locations (1)

19104-4283

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

Sponsors

Collaborators (2)

Sanofi
Bayer
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00589420 - Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy | Biotech Hunter | Biotech Hunter